Navigation Links
Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma
Date:5/29/2015

MILWAUKEE, WISCONSIN (PRWEB) May 29, 2015

Results from a Phase III clinical trial examining the oncolytic virus talimogene laherparepvec and its ability to reduce the size of melanoma tumors in patients injected with the treatment have been published in the Journal of Clinical Oncology.

The global, randomized trial enrolled 436 patients with stages IIIB, IIIC and IV melanoma, a potentially fatal form of skin cancer. The primary goal of the study was to evaluate the safety and efficacy of the oncolytic virus immunotherapy compared to patients treated with granulocyte-macrophage colony-stimulating factor (GM-CSF) alone.

As reported in 2013, talimogene laherparepvec did improve durable responses in patients with advanced melanoma. This was defined as an objective response (at least a 50 percent decrease in the size of both injected and un-injected tumors) within the first 12 months of treatment and lasting at least six months or more. Further, in patients who had an objective response, nearly 40 percent were complete responses.

“Talimogene laherparepvec or T-VEC could provide melanoma patients with another effective treatment option and supports further investigation of oncolytic viruses for other types of cancers,” said global principal investigator Howard L. Kaufman, MD, associate director for Clinical Science at the Rutgers Cancer Institute of New Jersey and president of the Society for Immunotherapy of Cancer (SITC). “The safety profile observed with T-VEC also supports combination studies with other immunotherapy agents."

T-VEC is a version of the herpes simplex virus that has been genetically modified to attenuate the virus, increase selectivity for cancer cells, and secrete cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF is a protein that is naturally secreted in the body that initiates an immune response. The virus invades both cancerous and healthy cells, but is unable to replicate in healthy cells, which remain unharmed. Inside a cancer cell, the virus is able to replicate, secreting GM-CSF in the process. Eventually overwhelmed, the cancer cell ruptures, destroying the cell and releasing new viruses, GM-CSF, and an array of tumor-specific antigens.

As president of the Society of Immunotherapy of Cancer, Dr. Kaufman credits SITC for advancing the science of immunotherapy by serving as a unifying force and collective voice of the entire cancer immunotherapy field. Several SITC members collaborated in the study of talimogene laherparepvec.

###

About SITC
Founded in 1984, Society for Immunotherapy of Cancer (SITC) is a non-profit medical society dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy through the core values of interaction, innovation and leadership. For more information on SITC, visit the Society website at http://www.sitcancer.org.

Read the full story at http://www.prweb.com/releases/2015/05/prweb12754262.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Study: Brain Imaging After Mild Head Injury/Concussion Can Show Lesions
2. University of Colorado Cancer Center Study Shows that Bitter Melon Juice Prevents Pancreatic Cancer in Mouse Models
3. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
4. Foundation For the NIH Joins NIH In Seeking Proposals to Study Sports-Related Brain Injuries
5. Janssen Announces Data from Simeprevir in Hepatitis C Patients Will Be Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
6. Trigemina Receives ISP Approval of Clinical Study Protocol for TI-001 Phase 2 Trial
7. Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
8. Study Says Bed Bugs Show Resistance to Pesticides, My Cleaning Products Asserts Non-Pesticide Bed Bug Bully Is the Better Pick Against the Pests
9. A bright idea: Tiny injectable LEDs help neuroscientists study the brain
10. NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinsons Disease
11. Study Says Kidney Bean Leaves Work Against Bed Bugs, My Cleaning Products Compares Its With a Non-Pesticide Bed Bug Spray
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/27/2020)... ... January 27, 2020 , ... Valencell, the ... from strategic investors led by Halma plc , a FTSE 100 global ... Ventures, GII LLC, and WSJ Joshua Fund. A representative from Halma will join ...
(Date:1/24/2020)... (PRWEB) , ... January 24, 2020 , ... ... innovations created by companies in biotechnology, diagnostics, therapeutics, laboratory and clinical services during ... millions of people around the world. And as Slone Partners celebrates ...
(Date:1/23/2020)... , ... January 22, 2020 , ... ... developments in the cosmetic surgery industry at two recent North American investor forums ... at the Canaccord Genuity Medical Technologies & Diagnostics Forum on November 21, 2019 ...
(Date:1/22/2020)... ... January 21, 2020 , ... Microbial Discovery Group LLC (MDG) ... Industrial and Institutional (I&I) Account Manager. Darrell will focus on servicing MDG’s partners ... over 30 years of sales experience working across multiple different market sectors such ...
Breaking Biology Technology:
(Date:12/21/2019)... ... 2019 , ... The City of Tampa recently served as the host location ... these heroes. Tampa welcomed these most-highly decorated USA heroes as the National Hockey League ... distinguished service members. , The Medal of Honor, the USA military’s highest award for ...
(Date:12/18/2019)... ... December 18, 2019 , ... Intelligent.com, a ... Top 10 Master's in Biotechnology Degree Programs for 2020. The comprehensive research guide ... nation. Each program is evaluated based on curriculum quality, graduation rate, reputation, and ...
(Date:12/4/2019)... Switzerland (PRWEB) , ... December 03, 2019 , ... ... biopharmaceutical R&D, today announced that Agenus , a clinical-stage immuno-oncology company developing ... of their antibody R&D workflow platform. Agenus will use the platform to support ...
Breaking Biology News(10 mins):